AZITHROMYCIN POWDER FOR SOLUTION
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
14-01-2014
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
AZITHROMYCIN
제공처:
DOMINION PHARMACAL
ATC 코드:
J01FA10
INN (국제 이름):
AZITHROMYCIN
복용량:
200MG
약제 형태:
POWDER FOR SOLUTION
구성:
AZITHROMYCIN 200MG
관리 경로:
ORAL
패키지 단위:
15/22.5ML
처방전 유형:
Prescription
치료 영역:
OTHER MACROLIDES
제품 요약:
Active ingredient group (AIG) number: 0126072003; AHFS:
승인 상태:
CANCELLED PRE MARKET
승인 날짜:
2019-06-17
제품 특성 요약
PRODUCT MONOGRAPH
PR
AZITHROMYCIN
Azithromycin dihydrate
(Powder for Oral Suspension 100 mg azithromycin/5 mL and 200 mg
azithromycin/5 mL) USP
Antibacterial Agent
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
1-888-550-6060
Date of Preparation:
December 17, 2013
Submission Control No: 170490
_ _
AZITHROMYCIN_ Product Monograph _
_Page_
_ _
_2 of 69_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
21
OVERDOSAGE
........................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
26
STORAGE AND STABILITY
.................................................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 30
PART II: SCIENTIFIC INFORMATION
...............................................................................
31
PHARMACEUTICAL INFORMATION
.................................................................................
31
CLINICAL TRIALS
.
전체 문서 읽기
